
|Articles|April 24, 2004
Genentech enrolling patients for Lucentis clinical trial
Genentech, South San Francisco, CA, announced that the biotechnologycompany is enrolling patients into a Phase III clinical trial for its age-relatedmacular degeneration (AMD) drug Lucentis (ranibizumab, rhuFab V2).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: The evolution of eye care on display at AAO 2025
2
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
3
Ocular pickleball injuries rise sharply with increasing game popularity
4
AAO 2025: Clinical outcomes of early vs delayed pegcetacoplan treatment in GA
5